Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications

Author(s):  Zur Eyal

Issue:  Nov/Dec 2018 - Volume 22, Number 6
View All Articles in Issue

Page(s):  446-454

Download in electronic PDF format for $65

Abstract:  Radiotherapy and epidermal growth factor receptor inhibitors, as important representatives of current chemotherapy, are crucial and irreplaceable treatments of modern oncology. These two types of treatments frequently cause severe dose-dependent dermatologic adverse events that can negatively affect a patient’s quality of life and compliance and cause inappropriate dose reductions and even treatment brakes. This article aims to emphasize new scientific data, published in peer reviews, regarding new possibilities to manage these debilitating dermatological adverse events. Since part of the scientific findings is new, the responsibility to enable pharmacologic treatment is in the compounding pharmacist domain. The article also suggests new formulations to the new pharmacologic treatment.

Related Keywords: Eyal Zur, BSc Pharm, RPh, MBA, cancer medicine, medical oncology, radiotherapy, epidermal growth factor receptor inhibitors, EGFR, dermatologic adverse events, acneiform rash, paronychia, inflammation, mucositis, xerosis, pruritus, hair changes, inflammatory changes, fingernails, keratinocytes, formulation, heparinoid cream, heparinoid lotion, topical preparations, ivermectin cream, ivermectin lotion, 5-aminolevulinic acid hydrochloride cream, case reports, radiation dermatitis, propranolol hydrochloride, topical corticosteroids


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum
Zur Eyal
Mar/Apr 2012
Pg. 117-124

Oral Mucositis: Etiology and Clinical and Pharmaceutical Management
Zur Eyal
Jan/Feb 2012
Pg. 22-33

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
Mar/Apr 2019
Pg. 113-119

Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol
McKettrick Greg
, Yoch Doug
Jan/Feb 2021
Pg. 18-23

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Low-dose Pilocarpine Spray to Treat Xerostomia
Zur Eyal
Mar/Apr 2020
Pg. 104-108

Imatinib 40-mg/mL Oral Suspension
Allen Loyd V Jr
Nov/Dec 2016
Pg. 510

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions